Skip to content

Investor Relations / Publications / Publications Search

Publications Search

Hilleman DE, Wiggins BS, Bottorff MB. A Response to: Letter to the Editor Regarding “Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review.” Adv Ther. 2020; epub ahead of print.

https://link.springer.com/article/10.1007/s12325-020-01420-z

American College of Cardiology
DL, Miller M, Steg G, et al. EPA levels and cardiovascular outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. Presented at the American College of Cardiology 2020 annual meeting (virtual).

https://www.acc.org/education-and-meetings/image-and-slide-gallery/media-detail?id=062fc9e4b3a74a9fb1c196a35dad8f3b

Mason RP, Sherratt SCR. Eicosapentaenoic acid inhibits oxidation of very large density lipoproteins (VLDL) in a dose-dependent manner over time as compared to docosahexaenoic acid in vitro [abstract]. J Am Coll Cardiol. 2020;75(11 suppl 1):2238.

http://www.onlinejacc.org/content/75/11_Supplement_1/2238

Sherratt SCR, Juliano RA, Mason RP. Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro. Biochimica Biophysica Acta Biomembrane. 2020; epub ahead of print.

https://www.sciencedirect.com/science/article/pii/S0005273620300791

Mason RP, Dawoud H, Jacob RF, Sherratt SCR, Malinski T. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statinBiomed Pharmacother. 2018;103:1231-7.
Free:

https://www.sciencedirect.com/science/article/pii/S0753332218309909

Mason RP, Sherratt SCR. Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits. Biochem Biophys Res Comm. 2017;483:425-429.
Free:

http://www.sciencedirect.com/science/article/pii/S0006291X16321878

Mason RP, Jacob RF, Shrivastava S, Sherratt SC, Chattopadhyay A. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochim Biophys Acta. 2016;1858:3131-3140.
Free:

http://www.sciencedirect.com/science/article/pii/S0005273616303297

Mason RP, Sherratt SCR, Jacob RF. Eicosapentaenoic acid inhibits oxidation of ApoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents. J Cardiovasc Pharmacol. 2016;68:33-40.
Free:

http://journals.lww.com/cardiovascularpharm/Fulltext/2016/07000/Eicosapentaenoic_Acid_Inhibits_Oxidation_of.5.aspx
copyright
© 2021, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
Spaces South Docklands
Block C
77 Sir John Rogerson's Quay
Dublin 2, D02 VK60
Investor Relations
AMARIN CORPORATION PLC C/O AMARIN PHARMA, INC.
440 ROUTE 22
BRIDGEWATER, NJ 08807
investor.relations@amarincorp.com
Fax:
+1 908 719 3012

Amarin Corporation